The field of gene therapeutics is really beginning to deliver, with dozens of pipeline treatments promising potentially revolutionary advances in patient outcomes. However, the innovative nature of this emerging category presents formidable challenges for developers, regulators, payers and patients.
In this report, Clarivate experts look at the calculations stakeholders are making to move these products from bench to bedside, ensure safety and efficacy, understand their value and make them accessible to the patients that most stand to benefit from them.
Download the report to learn more about: